Factor H-related proteins determine complement-activating surfaces

Trends in Immunology

Volumn 36, Issue 6, 2015, Pages 374-384

  Józsi, Mihály ^a   Tortajada, Agustin ^b,c   Uzonyi, Barbara ^d   Goicoechea de Jorge, Elena ^e,f,g   Rodríguez de Córdoba, Santiago ^b,c  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^d MTA ELTE Immunology Research Group Eötvös University   (Hungary)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f SCHOOL OF MEDICINE   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

CFHRs; Complement; Disease susceptibility; Factor H; Factor H related proteins

Indexed keywords

COMPLEMENT FACTOR H; COMPLEMENT FACTOR H RELATED PROTEIN; UNCLASSIFIED DRUG; APOLIPOPROTEIN; CFHR1 PROTEIN, HUMAN; CFHR2 PROTEIN, HUMAN; CFHR3 PROTEIN, HUMAN; CFHR4 PROTEIN, HUMAN; COMPLEMENT; COMPLEMENT FACTOR I; FHR5 PROTEIN, HUMAN; PLASMA PROTEIN;

ALTERNATIVE RNA SPLICING; ANTIGEN ANTIBODY COMPLEX; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; GENE CONVERSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; HOMOLOGOUS RECOMBINATION; HUMAN; NONHUMAN; OLIGOMERIZATION; PROTEIN FAMILY; REVIEW; BIOLOGICAL MODEL; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY;

APOLIPOPROTEINS; BLOOD PROTEINS; COMPLEMENT ACTIVATION; COMPLEMENT C3B INACTIVATOR PROTEINS; COMPLEMENT FACTOR H; COMPLEMENT SYSTEM PROTEINS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, IMMUNOLOGICAL;

EID: 84930819375     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.04.008     Document Type: Review

References (91)

1. Ricklin D., et al. Complement - a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
2. de Cordoba S.R., et al. Complement dysregulation and disease: from genes and proteins to diagnostics and drugs. Immunobiology 2012, 217:1034-1046.
3. Holers V.M. The spectrum of complement alternative pathway-mediated diseases. Immunol. Rev. 2008, 223:300-316.
4. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 2013, 190:3831-3838.
5. Sjoberg A.P., et al. Complement activation and inhibition: a delicate balance. Trends Immunol. 2009, 30:83-90.
6. Pérez-Caballero D., et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 2001, 68:478-484.
7. Józsi M., Zipfel P.F. Factor H family proteins and human diseases. Trends Immunol. 2008, 29:380-387.
8. Skerka C., Zipfel P.F. Complement factor H related proteins in immune diseases. Vaccine 2008, 26:I9-I14.
9. Zipfel P.F., et al. The factor H protein family. Immunopharmacology 1999, 42:53-60.
10. Goicoechea de Jorge E., et al. Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:4685-4690.
11. Tortajada A., et al. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J. Clin. Invest. 2013, 123:2434-2446.
12. Abarrategui-Garrido C., et al. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009, 114:4261-4271.
13. Abrera-Abeleda M.A., et al. Allelic variants of complement genes associated with dense deposit disease. J. Am. Soc. Nephrol. 2011, 22:1551-1559.
14. Chen Q., et al. Complement factor H-related hybrid protein deregulates complement in dense deposit disease. J. Clin. Invest. 2014, 124:145-155.
15. Gale D.P., et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010, 376:794-801.
16. Gharavi A.G., et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat. Genet. 2011, 43:321-327.
17. Hughes A.E., et al. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat. Genet. 2006, 38:1173-1177.
18. Maga T.K., et al. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum. Mutat. 2010, 31:E1445-E1460.
19. Malik T.H., et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J. Am. Soc. Nephrol. 2012, 23:1155-1160.
20. Martínez-Barricarte R., et al. Relevance of complement factor H-related 1 (CFHR1) genotypes in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2012, 53:1087-1094.
21. Monteferrante G., et al. Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. Mol. Immunol. 2007, 44:1704-1708.
22. Narendra U., et al. Genetic analysis of complement factor H related 5, CFHR5, in patients with age-related macular degeneration. Mol. Vis. 2009, 15:731-736.
23. Westra D., et al. Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 gene. J. Hum. Genet. 2012, 57:459-464.
24. Zhao J., et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet. 2011, 7:e1002079.
25. Heinen S., et al. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum. Mutat. 2006, 27:292-293.
26. Román-Ortiz E., et al. Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene. Pediatr. Nephrol. 2014, 29:149-153.
27. Sánchez-Corral P., et al. Functional analysis in serum from atypical hemolytic uremic syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol. Immunol. 2004, 41:81-84.
28. Venables J.P., et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med. 2006, 3:e431.
29. Valoti E., et al. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. J. Am. Soc. Nephrol. 2015, 26:209-219.
30. Hebecker M., et al. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. J. Immunol. 2013, 191:912-921.
31. Herbert A.P., et al. Structural and functional characterization of the product of disease-related factor H gene conversion. Biochemistry 2012, 51:1874-1884.
32. Holmes L.V., et al. Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32. PLoS ONE 2013, 8:e60352.
33. Hageman G.S., et al. Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Ann. Med. 2006, 38:592-604.
34. Kiryluk K., et al. Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies. Annu. Rev. Med. 2013, 64:339-356.
35. Jodele S., et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013, 122:2003-2007.
36. Athanasiou Y., et al. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin. J. Am. Soc. Nephrol. 2011, 6:1436-1446.
37. Gale D.P., Pickering M.C. Regulating complement in the kidney: insights from CFHR5 nephropathy. Dis. Model. Mech. 2011, 4:721-726.
38. Zipfel P.F., Skerka C. Complement factor H and related proteins: an expanding family of complement-regulatory proteins?. Immunol. Today 1994, 15:121-126.
39. Timmann C., et al. Two major serum components antigenically related to complement factor H are different glycosylation forms of a single protein with no factor H-like complement regulatory functions. J. Immunol. 1991, 146:1265-1270.
40. Hellwage J., et al. Functional properties of complement factor H-related proteins FHR-3 and FHR-4: binding to the C3d region of C3b and differential regulation by heparin. FEBS Lett. 1999, 462:345-352.
41. McRae J.L., et al. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein. J. Immunol. 2005, 174:6250-6256.
42. Fritsche L.G., et al. An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum. Mol. Genet. 2010, 19:4694-4704.
43. Pouw R.B., et al. Highly specific monoclonal antibodies against factor H-related protein 3. Mol. Immunol. 2014, 61:258.
44. Eberhardt H.U., et al. Human factor H-related protein 2 (CFHR2) regulates complement activation. PLoS ONE 2013, 8:e78617.
45. Heinen S., et al. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009, 114:2439-2447.
46. Strobel S., et al. Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome. Kidney Int. 2011, 80:397-404.
47. Caesar J.J.E., et al. Competition between antagonistic complement factors for a single protein on N. meningitidis rules disease susceptibility. Elife 2014, 3:e04008.
48. Siegel C., et al. Complement factor H-related proteins CFHR2 and CFHR5 represent novel ligands for the infection-associated CRASP proteins of Borrelia burgdorferi. PLoS ONE 2010, 5:e13519.
49. Schneider M.C., et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 2009, 458:890-893.
50. Davila S., et al. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat. Genet. 2010, 42:772-776.
51. Hebecker M., et al. Molecular basis of C-reactive protein binding and modulation of complement activation by factor H-related protein 4. Mol. Immunol. 2010, 47:1347-1355.
52. Mihlan M., et al. Human complement factor H-related protein 4 binds and recruits native pentameric C-reactive protein to necrotic cells. Mol. Immunol. 2009, 46:335-344.
53. Hakobyan S., et al. Complement factor H binds to denatured rather than to native pentameric C-reactive protein. J. Biol. Chem. 2008, 283:30451-33060.
54. Okemefuna A.I., et al. Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J. Biol. Chem. 2010, 285:1053-1065.
55. Hebecker M., Jozsi M. Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein. J. Biol. Chem. 2012, 287:19528-19536.
56. Losse J., et al. Factor H and factor H-related protein 1 bind to human neutrophils via complement receptor 3, mediate attachment to Candida albicans, and enhance neutrophil antimicrobial activity. J. Immunol. 2010, 184:912-921.
57. Friberg N., et al. Factor H binding as a complement evasion mechanism for an anaerobic pathogen, Fusobacterium necrophorum. J. Immunol. 2008, 181:8624-8632.
58. Blaum B.S., et al. Structural basis for sialic acid-mediated self-recognition by complement factor H. Nat. Chem. Biol. 2015, 11:77-82.
59. Thurman J.M., et al. Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury. J. Biol. Chem. 2009, 284:16939-16947.
60. Esparza-Gordillo J., et al. Genetic and environmental factors influencing the human factor H plasma levels. Immunogenetics 2004, 56:77-82.
61. Zhu L., et al. Variants in complement factor H and complement factor H-related protein genes, CFHR3 and CFHR1, affect complement activation in IgA nephropathy. J. Am. Soc. Nephrol. 2015, 26:1195-1204.
62. Li J.F., et al. Upregulation of microRNA-146a by hepatitis B virus X protein contributes to hepatitis development by downregulating complement factor H. MBio 2015, 6:e02459-e2514.
63. Närkiö-Mäkelä M., et al. Complement-regulator factor H and related proteins in otitis media with effusion. Clin. Immunol. 2001, 100:118-126.
64. Artuso R., et al. Investigation of modifier genes within copy number variations in Rett syndrome. J. Hum. Genet. 2011, 56:508-515.
65. Corbett B.A., et al. A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteins. Mol. Psychiatry 2007, 12:292-306.
66. Zhang Y., et al. A novel fusion gene CHFR5-CFHR2 causes C3 glomerulonephritis. Mol. Immunol. 2013, 56:297.
67. Clark S.J., et al. Identification of factor H-like protein 1 as the predominant complement regulator in Bruch's membrane: implications for age-related macular degeneration. J. Immunol. 2014, 193:4962-4970.
68. Csincsi A.I., et al. Factor H-related protein 5 interacts with pentraxin 3 and the extracellular matrix and modulates complement activation. J. Immunol. 2015, 194:4963-4973.
69. Kopp A., et al. Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor H and factor H-related protein 1 to pentraxin 3. J. Immunol. 2012, 189:1858-1867.
70. Esterbauer H., et al. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991, 11:81-128.
71. Weismann D., et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 2011, 478:76-81.
72. Edwards A.O., et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005, 308:421-424.
73. Hageman G.S., et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:7227-7232.
74. Haines J.L., et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005, 308:419-421.
75. Klein R.J., et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005, 308:385-389.
76. Wyatt R.J., Julian B.A. IgA nephropathy. N. Engl. J. Med. 2013, 368:2402-2414.
77. Kiryluk K., Novak J. The genetics and immunobiology of IgA nephropathy. J. Clin. Invest. 2014, 124:2325-2332.
78. Roos A., et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J. Am. Soc. Nephrol. 2006, 17:1724-1734.
79. Foltyn Zadura A., et al. Factor H autoantibodies and deletion of complement factor H-related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome. Arthritis Res. Ther. 2012, 14:R185.
80. Lachmann P.J. The amplification loop of the complement pathways. Adv. Immunol. 2009, 104:115-149.
81. Spitzer D., et al. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J. Immunol. 2007, 179:2600-2608.
82. Rodríguez de Córdoba S., et al. The human complement factor H: functional roles, genetic variations and disease associations. Mol. Immunol. 2004, 41:355-367.
83. Zipfel P.F., et al. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol. Immunol. 2006, 43:97-106.
84. Blanc C., et al. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J. Immunol. 2012, 189:3528-3537.
85. Park C.T., Wright S.D. Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein A-I, phospholipid, and factor H-related proteins. J. Biol. Chem. 1996, 271:18054-18060.
86. Skerka C., et al. The human factor H-related protein 4 (FHR-4). A novel short consensus repeat-containing protein is associated with human triglyceride-rich lipoproteins. J. Biol. Chem. 1997, 272:5627-5634.
87. Eyler S., et al. A novel hybrid CFHR1/CFH gene causes atypical hemolytic uremic syndrome. Pediatr. Nephrol. 2013, 28:2221-2225.
88. Francis N.J., et al. A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood 2012, 119:591-601.
89. Moore I., et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010, 115:379-387.
90. Zipfel P.F., et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 2007, 3:e41.
91. Medjeral-Thomas N.R., et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin. J. Am. Soc. Nephrol. 2014, 9:46-53.